Nimotuzumab in Combination With Chemoradiation for Esophageal Cancer
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located
in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical
efficacy has been shown in adult with head and neck cancer. The phase I study assessed the
safety, and efficacy of the combination of Nimotuzumab administered concomitantly with
chemo-radiotherapy in patients with locally advanced esophageal cancer tumours.